Latest news with #ViemedHealthcare
Yahoo
6 days ago
- Business
- Yahoo
3 Growth Companies With Insider Stakes As High As 20%
The market has been flat over the last week but is up 13% over the past year, with earnings forecast to grow by 14% annually. In this environment, stocks with significant insider ownership can be appealing as they often indicate confidence from those closest to the company's operations and potential for growth. Name Insider Ownership Earnings Growth Atour Lifestyle Holdings (NasdaqGS:ATAT) 22.7% 24.1% Super Micro Computer (NasdaqGS:SMCI) 16.2% 39.1% Duolingo (NasdaqGS:DUOL) 14.3% 39.9% FTC Solar (NasdaqCM:FTCI) 27.9% 62.5% Credo Technology Group Holding (NasdaqGS:CRDO) 12.1% 45% Astera Labs (NasdaqGS:ALAB) 15.1% 44.4% Prairie Operating (NasdaqCM:PROP) 34.2% 71.1% Enovix (NasdaqGS:ENVX) 12.1% 58.4% Hesai Group (NasdaqGS:HSAI) 21.3% 45.5% ARS Pharmaceuticals (NasdaqGM:SPRY) 14.3% 60.6% Click here to see the full list of 190 stocks from our Fast Growing US Companies With High Insider Ownership screener. Here's a peek at a few of the choices from the screener. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Viemed Healthcare, Inc. operates in the United States, offering home medical equipment and post-acute respiratory healthcare services, with a market cap of $259.28 million. Operations: The company generates revenue of $232.79 million from its Sleep and Respiratory Disorders Sector. Insider Ownership: 12.8% Viemed Healthcare exhibits strong growth potential with earnings forecasted to grow 26.2% annually, outpacing the US market. Recent earnings reports show increased sales and net income, with Q1 2025 sales at US$59.13 million and net income at US$2.63 million, reflecting solid performance year-over-year. Despite significant insider selling in the past quarter, insider buying has outweighed it recently, indicating confidence in future prospects amidst raised revenue guidance for 2025 up to US$265 million. Click to explore a detailed breakdown of our findings in Viemed Healthcare's earnings growth report. In light of our recent valuation report, it seems possible that Viemed Healthcare is trading behind its estimated value. Simply Wall St Growth Rating: ★★★★★☆ Overview: United States Antimony Corporation is involved in the production and sale of antimony, zeolite, and precious metals in the United States and Canada, with a market cap of $298.35 million. Operations: The company generates revenue from its antimony segment at $15.43 million and its zeolite segment at $3.43 million. Insider Ownership: 17.6% United States Antimony is positioned for substantial growth, with revenue expected to increase by 50.8% annually, surpassing the US market's average. The company recently reported a significant rise in Q1 sales to US$7 million and turned profitable with a net income of US$0.55 million compared to last year's loss. Despite recent share price volatility and no significant insider trading activity, analysts anticipate an 85.6% stock price increase, reflecting optimism about future profitability within three years. Click here and access our complete growth analysis report to understand the dynamics of United States Antimony. Insights from our recent valuation report point to the potential overvaluation of United States Antimony shares in the market. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Youdao, Inc. is an internet technology company offering online services in content, community, communication, and commerce in China with a market cap of approximately $1.07 billion. Operations: The company's revenue is primarily derived from Learning Services (CN¥2.63 billion), Online Marketing Services (CN¥1.99 billion), and Smart Devices (CN¥912.97 million). Insider Ownership: 20.4% Youdao's earnings are forecast to grow at 35.7% annually, outpacing the US market average of 14.4%, while revenue growth is expected at 11.3% per year, slightly above the market rate. Despite becoming profitable this year, debt coverage by operating cash flow remains inadequate. No insider trading activity was noted recently, but a share buyback of 6.19% for US$33.8 million has been completed since November 2022, indicating confidence in long-term growth prospects. Delve into the full analysis future growth report here for a deeper understanding of Youdao. Our valuation report unveils the possibility Youdao's shares may be trading at a premium. Get an in-depth perspective on all 190 Fast Growing US Companies With High Insider Ownership by using our screener here. Looking For Alternative Opportunities? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years. Companies discussed in this article include NasdaqCM:VMD NYSEAM:UAMY and NYSE:DAO. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
05-05-2025
- Business
- Yahoo
Jim Cramer on Viemed Healthcare (VMD): 'Interesting, But I'm a ResMed Guy'
We recently published a list of . In this article, we are going to take a look at where Viemed Healthcare, Inc. (NASDAQ:VMD) stands against other stocks that Jim Cramer discussed. On Thursday's episode of Mad Money, Jim Cramer voiced his exasperation over the skepticism surrounding AI infrastructure as he stated that it was never backed by solid evidence to begin with. He expressed frustration that so many investors had been misled into believing that the AI infrastructure boom had somehow stalled. 'Earnings season, it's a pain in the neck. It's convoluted stuff coming at you from all different directions. Loss of sleep, just a total time suck and I love it. I love it because it clears things up. The false narratives are exposed. You can go back to playing offense, not defense. And few false narratives have gone as far as this story about the end of data center spending.' READ ALSO: 8 Stocks on Jim Cramer's Radar Recently and Jim Cramer Listed 20 Best Performing Stocks of the Last 20 Years According to Cramer, the story took root back on January 27th, 'DeepSeek Monday,' when a Chinese company said that they developed a generative AI model requiring significantly fewer computing resources than industry leaders. He added: 'All the previously red-hot AI infrastructure stocks were immediately crushed. You know what? They never really recovered.' Cramer questioned how the doubt could have been spread so easily. He pointed to the media's role and wondered whether reporters asked the right questions or enough questions at all. He criticized the consistent spotlight given to bearish voices, many of whom had clear financial motives. As per Cramer, some of these commentators failed to disclose that they had short positions across the AI sector. He accused them of putting profits ahead of facts as he noted that too much money was at stake for them to let reality interfere with their narrative. He added: 'I know it may be hard to believe that huge companies with tens of billions of dollars to spend actually keep funneling that money to the data center suppliers… but that's exactly what's happening, and I think it's not too late to own a lot of the members of the complex. Even as I expect that if we wait a few days, the bears will be out again… They just can't stop trying to make money at your expense.' For this article, we compiled a list of 13 stocks that were discussed by Jim Cramer during the episodes of Mad Money aired on April 30 and May 1. We listed the stocks in ascending order of their hedge fund sentiment as of the fourth quarter of 2024, which was taken from Insider Monkey's database of over 1,000 hedge funds. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (). A patient receiving oxygen concentrator treatment for chronic obstructive pulmonary disease. Number of Hedge Fund Holders: 14 Upon a caller's inquiry about Viemed Healthcare, Inc. (NASDAQ:VMD), Cramer said in response: 'Very interesting. And you know, look, I'm a Resmed guy. I don't know VieMed well enough, but I'm glad you, look, you've done the work. I've not. It's from Lafayette, Louisiana, interesting company.' Viemed Healthcare (NASDAQ:VMD) provides respiratory care and home medical equipment, including ventilators and oxygen therapy, with services focused on managing conditions like COPD and sleep apnea. It also offers sleep testing and healthcare staffing. As per the company's full year 2025 guidance, net revenue is projected to fall between $254 million and $265 million. Adjusted EBITDA for the same period is expected to range from $54 million to $58 million. Overall, VMD ranks 13th on our list of stocks that Jim Cramer discussed. While we acknowledge the potential of VMD as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than VMD but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
22-04-2025
- Business
- Yahoo
Viemed Healthcare Announces First Quarter 2025 Earnings Conference Call Details
LAFAYETTE, La., April 22, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the 'Company' or 'Viemed') (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, today announced that it will host its First Quarter 2025 Earnings Conference Call on Thursday, May 8, 2025, at 11:00 a.m. EDT. Interested parties may participate in the call by dialing: (866) 682-6100 (US Toll-Free) +1 (862) 298-0702 (International) Live Audio Webcast: Following the live call, a replay will be available in the Investor Relations section of the Company's website at ABOUT VIEMED HEALTHCARE, INC. Viemed is an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States, including non-invasive ventilators (NIV), sleep therapy, staffing, and other complementary products and services. Viemed focuses on efficient and effective in-home treatment with clinical practitioners providing therapy, education and counseling to patients in their homes using high-touch and high-tech services. Visit our website at For further information, please contact: Tripp SullivanSCR Partners, LLC615-942-7077tsullivan@ Todd ZehnderChief Operating OfficerViemed Healthcare, Inc.337-504-3802investorinfo@ in to access your portfolio
Yahoo
30-03-2025
- Business
- Yahoo
Viemed Healthcare, Inc. (VMD): A Bull Case Theory
We came across a bullish thesis on Viemed Healthcare, Inc. (VMD) on Substack by Petty Cash. In this article, we will summarize the bulls' thesis on VMD. Viemed Healthcare, Inc. (VMD)'s share was trading at $7.25 as of March 27th. VMD's trailing P/E was 25.89 according to Yahoo Finance. A close-up of a medical technician wearing lab coat and a face mask preparing a portable oxygen concentrator for a patient. Viemed Healthcare (VMD) reported solid quarterly results, surpassing expectations and driving a modest stock increase of 3-4%. Revenue reached $60.7 million, while EBITDA improved to $14.2 million from $12.8 million. Patient metrics remained strong, with ventilator patients growing 14% year-over-year and 4% sequentially to 11,795, while PAP therapy and sleep resupply patient counts saw impressive growth, rising 43% and 29% year-over-year, respectively. For the first time, VMD issued full-year guidance, projecting $254-265 million in revenue and $54-58 million in EBITDA, reflecting a 16% and 10% increase at the midpoint. Management noted typical seasonality, with Q1 softer than Q4 before ramping up. The company continues its transition from a traditional home medical equipment (HME) provider to an in-home clinical care provider. While uncertain about the impact of tariffs and regulatory changes under the new administration, management remains confident in VMD's positioning amid broader healthcare cost-efficiency trends. The joint venture with East Alabama Medical is progressing well, and larger JV opportunities may emerge. The M&A landscape has improved compared to previous years, offering potential expansion opportunities. The market for VMD's ventilation and sleep apnea treatments remains underpenetrated, presenting a significant runway for growth. COPD affects 25 million people in the U.S., with 1.25 million in chronic respiratory failure requiring ventilation, yet industry penetration remains in the high single digits. Similarly, sleep apnea remains widely underdiagnosed, and the rise of GLP-1 medications has increased patient awareness and demand for PAP therapy, driving recurring resupply revenue. Despite strong execution and growth, VMD trades at a compelling 6x EV/EBITDA trailing and 5.5x forward, near its post-COVID lows. While the company requires capital for expansion, its organic growth, improving M&A environment, and undervaluation make it an attractive investment. Viemed Healthcare, Inc. (VMD) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 14 hedge fund portfolios held VMD at the end of the fourth quarter which was 9 in the previous quarter. While we acknowledge the risk and potential of VMD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than VMD but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
25-02-2025
- Business
- Yahoo
Viemed Healthcare Announces Year End 2024 Earnings Conference Call Details
LAFAYETTE, La., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the 'Company' or 'Viemed') (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, today announced that it will host its Year End 2024 earnings conference call on Tuesday, March 11, 2025, at 11:00 a.m. EDT. Interested parties may participate in the call by dialing: 877-407-6176 (US Toll-Free) +1 201-689-8451 (International) Live Audio Webcast: Following the live call, a replay will be available in the Investor Relations section of the Company's website at ABOUT VIEMED HEALTHCARE, INC. Viemed is an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States, including non-invasive ventilators (NIV), sleep therapy, staffing, and other complementary products and services. Viemed focuses on efficient and effective in-home treatment with clinical practitioners providing therapy, education and counseling to patients in their homes using high-touch and high-tech services. Visit our website at For further information, please contact: Tripp SullivanSCR Partners, LLC615-942-7077tsullivan@ Todd ZehnderChief Operating OfficerViemed Healthcare, Inc.337-504-3802investorinfo@ in to access your portfolio
